Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia.
Nepean Kidney Research Centre, Department of Renal Medicine, Nepean Hospital, Sydney, NSW, Australia.
J Nephrol. 2023 Sep;36(7):1841-1859. doi: 10.1007/s40620-023-01716-7. Epub 2023 Aug 7.
This systematic review summarises the stability of less commonly prescribed antibiotics in different peritoneal dialysis solutions that could be used for culture-directed therapy of peritonitis, which would be especially useful in regions with a high prevalence of multidrug antibiotic-resistant strains.
A literature search of Medline, Scopus, Embase and Google Scholar for articles published from inception to 25 January, 2023 was conducted. Only antibiotic stability studies conducted in vitro and not recently reviewed by So et al. were included. The main outcomes were chemical, physical, antimicrobial and microbial stability. This protocol was registered in PROSPERO (registration number CRD42023393366).
We screened 1254 abstracts, and 28 articles were included in the study. In addition to those discussed in a recent systematic review (So et al., Clin Kidney J 15(6):1071-1078, 2022), we identified 18 antimicrobial agents. Of these, 9 have intraperitoneal dosing recommendations in the recent International Society for Peritoneal Dialysis (ISPD) peritonitis guidelines, and 7 of the 9 had stability data applicable to clinical practice. They were cefotaxime, ceftriaxone, daptomycin, ofloxacin, and teicoplanin in glucose-based solutions, tobramycin in Extraneal solution only and fosfomycin in Extraneal, Nutrineal, Physioneal 1.36% and 2.27% glucose solutions.
Physicochemical stability has not been demonstrated for all antibiotics with intraperitoneal dosing recommendations in the ISPD peritonitis guidelines. Further studies are required to determine the stability of antibiotics, especially in icodextrin-based and low-glucose degradation products, pH-neutral solutions.
本系统评价总结了不同腹膜透析液中较少使用的抗生素的稳定性,这些抗生素可用于指导腹膜炎的培养治疗,这在多药耐药抗生素耐药株高发地区尤为有用。
对 Medline、Scopus、Embase 和 Google Scholar 进行了文献检索,检索时间为从建库至 2023 年 1 月 25 日发表的文章。仅纳入了在体外进行且尚未被 So 等人最近综述的抗生素稳定性研究。主要结局为化学、物理、抗菌和微生物稳定性。本方案已在 PROSPERO(注册号 CRD42023393366)中注册。
我们筛选了 1254 篇摘要,纳入了 28 篇文章进行研究。除了 So 等人最近的系统评价(Clin Kidney J 15(6):1071-1078, 2022)中讨论的那些药物外,我们还确定了 18 种抗菌药物。其中,9 种药物在最近的国际腹膜透析学会(ISPD)腹膜炎指南中有腹腔内给药推荐,其中 7 种药物的稳定性数据适用于临床实践。这些药物包括葡萄糖基溶液中的头孢噻肟、头孢曲松、达托霉素、氧氟沙星和替考拉宁,仅在 Extraneal 溶液中的妥布霉素,以及 Extraneal、Nutrineal、Physioneal 1.36%和 2.27%葡萄糖溶液中的磷霉素。
并非所有 ISPD 腹膜炎指南中推荐腹腔内给药的抗生素都已证明具有物理化学稳定性。需要进一步研究来确定抗生素的稳定性,特别是在基于艾考糊精和低葡萄糖降解产物、中性 pH 值的溶液中的稳定性。